US private equity group nears deal for pharma spin-off after edging out PAI-led consortium
Agreement over heartburn medicine should help to resolve concerns hanging over UK drugmaker
A seemingly misfired message has embroiled Albert Bourla and his company in a high-stakes activist battle
A big market narrative with an eerie absence of sceptics
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain
Hedge fund had enlisted help from ex-chair Ian Read and former finance chief Frank D’Amelio
CBO analysis says savings from other health benefits would not offset the expense of weight-loss jabs
Fund run by Jeff Smith builds $1bn stake in vaccine maker and pitches shake-up plan
The drugmaker is worth less now than before the pandemic
Plus, Jane Street comes for Goldman’s trading crown and Byju’s can’t find the money
Ian Read has called his successors about the activist’s ideas for turning round the vaccine maker
Pharma giant’s share price has fallen below pre-pandemic levels after shortlived bump from Covid vaccine
US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
Weight loss drugs appear to be having an effect at the population level
Drugmakers have been targeted on national security grounds and could lose customers if Congress passes Biosecure Act
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
Weight-loss drugs and a new focus on wellness are pushing many exercise machines towards obsolescence
Artificial intelligence used to help researchers plan experiments and better predict outcomes
Drugmaker’s CEO sees chance to widen use of anti-obesity medications for ‘health maintenance’
Interest of PE groups in Sanofi’s Opella highlights the renewed ebullience of debt financiers
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
The reduced effectiveness of antibiotics risks severe disruption to the global economy
Joe Kiani asserts in a California lawsuit that he is entitled to severance under provisions typically tied to a company sale
The lessons learnt from drug-resistant tuberculosis offer a path to beating back the ‘silent pandemic’ of antimicrobial resistance
Emmanuel Hanon criticises former company’s drug after he raises $100mn for rival product
